Feasibility and effectiveness of transcatheter aortic valve implantation in adults with congenital heart disease by Moharem-Elgamal, Sarah et al.
                          Moharem-Elgamal, S., Yeong, M., Veerappan, S., Manghat, N. E.,
Bedair, R., Dorman, S., Caputo, M., Hamilton, M. C. K., & Turner, M.
(2021). Feasibility and effectiveness of transcatheter aortic valve
implantation in adults with congenital heart disease. International
Journal of Cardiology Congenital Heart Disease.
https://doi.org/10.1016/j.ijcchd.2021.100116
Publisher's PDF, also known as Version of record
License (if available):
CC BY-NC-ND
Link to published version (if available):
10.1016/j.ijcchd.2021.100116
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Elsevier at
10.1016/j.ijcchd.2021.100116. Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
International Journal of Cardiology Congenital Heart Disease 3 (2021) 100116Contents lists available at ScienceDirect
International Journal of Cardiology Congenital Heart Disease
journal homepage: www.journals.elsevier.com/international-journal-of-cardiology-
congenital-heart-diseaseFeasibility and effectiveness of transcatheter aortic valve implantation in
adults with congenital heart disease
Sarah Moharem-Elgamal a,b,c,d, Michael Yeong a,b,e, Sundar Veerappan a, Nathan Manghat a,
Radwa Bedair a,b, Stephen Dorman a, Massimo Caputo a,b, Mark Hamilton a, Mark S. Turner a,*
a Bristol Heart Institute, University Hospitals Bristol NHS Trust, United Kingdom
b Bristol Medical School, University of Bristol, United Kingdom
c Cardiology Department, National Heart Institute, Giza, Egypt
d Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
e Mater Children's Private Hospital, Brisbane, AustraliaA R T I C L E I N F O
Keywords:
Aortic valve disease
Adult congenital heart disease
Transcatheter aortic valve replacement* Corresponding author. Cardiology Department,
E-mail address: markturner3@nhs.net (M.S. Tur
https://doi.org/10.1016/j.ijcchd.2021.100116
Received 26 February 2021; Accepted 10 March 20
2666-6685/© 2021 The Authors. Published by Else
nc-nd/4.0/).A B S T R A C T
Aim: This study sought to evaluate the feasibility and effectiveness of TAVI for treatment of aortic stenosis in the
ACHD population.
Methods and results: Review of 802 patients that underwent TAVI from January 2008 to November 2019. 13 ACHD
patients with different underlying congenital anatomy were identified (isolated bicuspid aortic valve was
excluded and not defined as ACHD). The main endpoints were: paravalvular aortic regurgitation> grade 2 post-
procedure, and all-cause 30-day mortality. Periprocedural and post-procedural complications were defined ac-
cording to the UK TAVI registry. Median age was 66.7 years (range 29–84 years). Eleven patients had severe
aortic stenosis (AS), 1 had both severe AS and severe aortic regurgitation (AR) and 1 had severe AR. Median
hospital stay was 9 days (range 6–28 days). One patient required a pacemaker post-TAVI. No mortality or par-
avalvular AR> grade 2 at 30-days. Twelve patients had a reduction in NYHA class on their first post TAVI follow-
up.
Conclusion: TAVI is viable option as an alternative to surgery for ACHD patients. Further experience with the use
of TAVI in the ACHD patients is required to assess long-term outcomes in this unique group of patients.1. Introduction
The past 70 years has witnessed considerable development in the
diagnosis and management of congenital heart disease, leading to an
increased number living into adulthood [1]. Despite increased survival,
adults with congenital heart disease (ACHD) often have complex anat-
omy, and have more cardiovascular complications and a higher mortality
risk than the general population [2,3]. Many will develop significant
valve lesions requiring multiple interventions in their lifetime.
Transcatheter aortic valve implantation (TAVI) was initially intro-
duced to treat elderly patients with calcific aortic stenosis who were
considered high risk or with contraindications to surgery [4]. The in-
dications for TAVI have expanded to those at intermediate and low risk
for conventional surgical valve replacement [5–7].
ACHD patients have frequently undergone sternotomies in childhood,
have unusual anatomy of the aortic valve, or the consequences ofBristol Heart Institute, Level 7, B
ner).
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vier B.V. This is an open access arprevious surgery, and may have access problems to the heart, such as the
presence of a coarctation repair (surgical or stent). Furthermore, as they
are often young, the longevity of whatever valve is implanted surgically
or percutaneously has to be taken into consideration.
TAVI has potential advantages for ACHD patients who have had
previous operations or other relative contraindications to surgery, but
TAVI for severe aortic valve (AoV) disease in the ACHD population is not
well described.
This study reports all TAVI procedures undertaken in ACHD patients
over an 11-year period at a tertiary level I centre for ACHD and TAVI.
2. Methods
2.1. Patients
We retrospectively reviewed the cardiac catheterization reports and
medical notes of all TAVI patients from January 2008 until NovemberRI, Upper Maudlin Street, Bristol, BS2 8HW, United Kingdom.
ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
Abbreviation list




BAV Bicuspid aortic valve
CoA Coarctation of aorta
CT Computed tomography
EuroSCORE European System for Cardiac Operative Risk
Evaluation
MDT Multi-Disciplinary Team meeting
NYHA New York Heart Association
PAR Paravalvular aortic regurgitation
TAVI Transcatheter Aortic Valve Implantation
TGA Transposition of great arteries
ViV Valve in Valve
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were identified from a total of 802 TAVI procedures during this period. A
total of 293 AoV surgical procedures were performed on ACHD patients
by comparison. Patients with native bicuspid aortic valve (BAV) alone as
their only congenital diagnosis were not included in our study. Baseline
demographic and clinical characteristics were recorded. All patients were
discussed at ACHD and TAVI Multi-Disciplinary Team meetings (MDT),
confirming an indication and mode of treatment (central illustration).
Eleven of the TAVI ACHD patients were deemed very high risk by the
surgical team. One patient refused blood transfusion and declined sur-
gery. In one patient, surgery was attempted, but cross clamping was not
feasible (because of significant scar tissue and risk of continued surgical
dissection,) and the surgeon requested TAVI. This retrospective service
evaluation was exempt from Research and Ethics Committee review in
accordance with National Health Service Research Ethics Service
guidelines [1].Table 1
Baseline characteristics, medical history and indication of TAVR.
Patient Diagnosis
1 Atrio-pulmonary Fontan, Tricuspid & pulmonary atresia, previous Brock procedure
Blalock Taussig shunt
2 CoA - surgical repair; severe bicuspid AS þ saccular calcified aneurysm at site of Co
3 Congenitally corrected TGA with systemic right ventricle dysfunction þ moderate
right atrioventricular valve regurgitation
4 Bicuspid AS, pulmonary hypertension due to PDA
5 Aortic homograft, previous infective endocarditis.
6 Double inlet left ventricle, TGA, S/P arterial switch þ Glenn, S/P total cavopulmo
connection, Ehlers Danlos syndrome.
7 Native CoA, bicuspid AS, Jehovah's witness
8 CoA surgical repair, recoarctation, bicuspid AoV replacement, bioprosthetic valve
degeneration-severe AS, previous atrial fibrillation and complete heart block, dual-
implantable cardioverter-defibrillator
9 Congenital bicuspid AoV, previous homograft AVR with severe prosthetic AS
10 Infective endocarditis and homograft AVR x2 childhood, presenting with cerebrov
accident þ severe AS and AR
11 Previous CoA surgical repair, tiny pseudoaneurysm, severe bicuspid AS, heavy calc
of ascending aorta, peripheral vascular disease, single functioning kidney
12 CoA, bicuspid AoV with root dilatation, previous bioprosthetic valve þ ascending
arch replacement), dilatation ascending aorta (52 mm) & aorta beyond aortic arch
replacement
13 Moderate-severe residual bicuspid AS, post sub-aortic resection and valvotomy, Ao
(3x sternotomy) & previous CoA repair (thoracotomy), residual AS and AR
2
2.2. Echocardiography
The diagnosis of severe AoV disease was confirmed by transthoracic
echocardiography according to established guidelines [2]. Prior to
discharge all patients received a detailed transthoracic echocardiogram
including peak velocity, peak and mean gradient, and systemic ventric-
ular ejection fraction.
Semi-quantitative grading of paravalvular AR (PAR) was performed
using periprocedural transoesophageal echocardiography and aortog-
raphy and post-procedure transthoracic echocardiography. Semi-
quantitative grading of PAR was; 0¼ absent, 1¼ trace, 2¼mild,
3¼moderate, 4¼ severe [3].2.3. Computed tomography
Prior to the procedure, all patients underwent CT to assess: 1) valve
morphology, 2) annulus size 3) coronary ostial height and sinus of Val-
salva assessment, 4) aortic root, 5) evaluation of the peripheral access
route.
CT scans were performed using ECG gating with either a Somatom
ASþ (Siemens Healthineers, Erlangen, Germany) or an Aquilion One
Genesis (Canon Medical Systems, Otawara, Japan) system. The Siemens
system is a 64-detector row system with flying focal spot, 0.6 mm colli-
mation, 300 ms rotation time, and the Canon system 320 detector row,
0.5 mm collimation, 270ms rotation time. Non-contrast evaluation of the
aortic root was not an essential component of the TAVI work-up as some
members of our patient population were young and been recommended
in recent guidelines as it is useful in the setting of uncertain AS severity. If
non-contrast scans were acquired, AoV calcium score was performed at
120 kV. In patients who did not have a non-contrast scan, severity of
calcium on contrast scans was based on visual assessment (supplemen-
tary data). Contrast enhanced CT scans were 100–120 kV retrospective
ECG gated examination of the aortic root (maximum tube output in
systole). Typically, 0.75 mm thick reconstructions were used for annular
assessment at 250ms and 75% phase (Canon) and 250ms and 70% phase
(Siemens). Assuming adequate renal function (eGFR >45) an iodine flux
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Fig. 1. Summary of TAVI in ACHD Feasibility Study. Evolut and Sapien XT images used with the courtesy and permission of Medtronic (© 2016 Medtronic) and
Edwards Lifesciences Corporation.
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Iomeron 400 (Bracco, Milan, Italy) or Omnipaque 300 (General Electric,
USA) iodinated contrast was used.
2.4. Vascular access and valve selection
The vascular approach was determined by the size, calcification,
tortuosity and patency of ilio-femoral arteries. Valve type was deter-
mined by the operator based on anatomical and clinical factors. Valve
size was based on pre-procedural imaging. If the patient had a prosthetic
valve, the size of the valve was based on true internal diameters of the
prothesis. From 2014, ViV (valve in valve) Aortic smart phone applica-
tion was used for planning ViV procedure (https://www.pcronline.co
m/PCR-Publications/PCR-mobileapps/Valve-in-Valve-Aortic-app) [4].
2.5. Procedure
TAVI procedures were performed in a hybrid cardiac catheterization
room under general anaesthesia or local anaesthesia with conscious
sedation. Transoesophageal echocardiography was used if the TAVI was
under general anaesthesia. Ultrasound guidance for vascular access was
used for femoral access. Both self-expanding and balloon expandable
valves were used, and pre-dilatation was performed at the operator's
discretion. Intravenous heparin was administered to achieve an ACT of
around 300s. The large vessel access was closed with a Prostar closure
device and pacing was established with a transvenous temporary pacing
wire. The result was assessed angiographically, hemodynamically and by
echocardiography.
2.6. Postprocedural care
All patients were observed in the coronary care unit or cardiac
intensive care unit for at least 24 h. For patients who did not have an3
indication for anti-coagulation, dual antiplatelet therapy was continued
for 3 months and, thereafter, aspirin was continued indefinitely.
2.7. Study outcomes
The main endpoints were the frequency of PAR> grade 2 post-
procedure and all-cause 30-day mortality. Periprocedural and post-
procedural complications were defined according to the UK TAVI regis-
try [5]. Adverse events were defined as myocardial infarction, major
stroke, acute kidney injury, major vascular complication, life-threatening
bleeding, annulus rupture and pacemaker implantation. Any other sig-
nificant event identified during follow up was also reported.
2.8. Statistical analysis
Statistical analysis was performed using commercial spread sheet
software. (Excel 2019 for Mac version 16.29, Microsoft, Redmond,
Washington). Continuous data were reported as mean SD or median
(range) depending on normality of their distribution. Categorical vari-
ables were presented as frequencies and percentages. Complete data
were available in all patients. Inferential statistical analyses were not
carried out, as the sample was too small and diverse.
3. Results
3.1. Baseline characteristics
Baseline characteristics, medical history and indication of TAVI are
summarized in Table 1. All 13 patients (9 males) had different underlying
congenital heart disease. All presented with decreased physical capacity
(average NYHA class III), 3 of whom as urgent inpatients. Eleven patients
had severe AS, 1 had both severe AS and severe aortic regurgitation (AR)
and 1 severe AR. Ten of the 13 (77%) had undergone previous cardiac
Fig. 2. TAVI in Fontan Circulation. Panel A–C preprocedural imaging, procedure and postprocedural imaging of Patient 1. Panel D–E preprocedural imaging and
procedure of Patient 6.
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Fig. 3. Vascular access in patients with a background diagnosis of CoA.
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inally had BAV) and 6 native BAV in addition to their underlying con-
dition. The aortic annulus size was 26.1mm 1.96 (range 23mm–31
mm). Patient 6 had an annulus of 33mm, but the superior aspect had
previously been resuspended in a 31mm Goretex tube during his previ-
ous valve sparing aortic root operation. In 12 patients with severe AS, the
pre-procedural mean gradient was 45mmHg12.8.
Some patients were elderly, but all had congenital anatomical ab-
normalities that had a potential technical challenge, setting them apart
from the usual TAVR population, including coarctation and an anterior
aorta connected to a systemic right ventricle, with a muscular right
ventricular outflow tract, below the aortic valve.
3.2. Procedural results
A summary of our approach and outcomes are shown in Fig. 1 and
results of imaging and procedural details for the 13 patients are sum-
marized in Table 2, some of which are illustrated in Figs. 2–5. Patient 1
has been published as a case report and only salient data is provided [6].
Eleven TAVI procedures were performed transfemorally. A trans-
apical approach was performed in patient 5 due to residual coarctation
and small peripheral vessels. Patient 5 also had an ejection fraction of5
~10% with non-compaction cardiomyopathy and so peripheral bypass
was established surgically with an apical vent. Patient 7 had subclavian
artery access as there was right external iliac occlusion from previous
native coarctation stenting.
Balloon-expandable valves were used in 2 patients (17%) (Sapien S3
and SapienXT, Edwards Lifesciences, Inc., Irvine, California and self-
expanding THV in 11 patients (83%) (CoreValve, Evolut R and Evolut
Pro Medtronic, Inc., Minneapolis, Minnesota).
Ten out of 13 procedures were uncomplicated. The complications
seen in the other 3 patients were the need of a pacemaker and significant
PAR (one valve repositioning and the other a second valve). Patient 1
experienced ventricular standstill after direct implantation of the 29mm
Medtronic Evolut R. She was the only patient who needed permanent
pacing (epicardial) [6]. Patient 3 developed significant PAR with wors-
ening systemic right ventricular function and renal impairment. He was
returned to the lab and the 31mm CoreValve was snared and pulled up
into a higher position, with improved diastolic blood pressure and mild
AR. Patient 6 required a second valve during the procedure. On multiple
attempts, the first valve went too deep or popped up. After good posi-
tioning of the first valve was achieved, the valve dived into the ventricle
after release. This resulted in severe AR and hemodynamic instability.
Attempts to pull the valve up with a balloon failed. As hemodynamics
Fig. 4. TAVI procedure in a homograft (upper and middle panel). Lower panel shows thrombus (arrows) detected during routine follow up scan.
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28mm Nucleus balloon was inflated in the valve to prevent retrograde
flow and improve the pressure on bypass (as the aortic regurgitation was
preventing effective perfusion), and a second valve was prepared. Suc-
cessful implantation of the second valve was achieved at a much higher
position with mild AR on transoesphageal echocardiogram and angiog-
raphy. Coronary ostial obstruction was not a feature in any case.
3.3. Clinical outcome
3.3.1. Primary safety and effectiveness end point
There was no mortality at 30 days, nor any myocardial infarction,
AKI, life-threatening bleeding or major vascular complications. The
median stay in hospital was 8.0 days (range 4–35 days). Twelve patients
were discharged directly home. Patient 6 who had an intraoperative
cardiac arrest and woke up with quite significant visual loss, dysarthria
and co-ordination difficulties. Ophthalmology review, CT and MRI head
were unremarkable. This was likely ischemic posterior optic neuropathy
and hypoxic brain injury. His vision gradually improved, and he was
discharged to a rehabilitation facility. Twelve patients reported
improvement in NYHA functional class at their first follow up. The mean
gradient was reduced to 15mmHg7.2. There was nomore thanmild AR
was reported on predischarge or first follow up transthoracic
echocardiography.6
3.3.2. Additional clinical outcomes
The median follow-up time was 2.9 years. Patient 1, with a back-
ground of atriopulmonary Fontan, experienced increased fatiguability
and her mild PAR progressed to moderate at her 3.6 years follow up.
Patient 5 died at 4 months post-TAVI from recurrent AoV endocarditis,
patient 3 died aged 84 with congenitally corrected TGA at 7 months post-
TAVI from sepsis and heart failure and patient 10 died from sepsis. Pa-
tient 4, who had severe pulmonary hypertension of 180mmHg, is well,
four years post TAVI. He had near normal systolic pulmonary artery
pressures 2-years post-procedure on right heart catherization assessment
and more recently had successful atrial flutter ablation. Incidentally at 4
months post TAVI, patient 9 (with a previous aortic homograft) was
found to have extensive thrombus formation within the inferior aspects
of all 3 aortic sinuses on CT which extended up to, but did not compro-
mise the coronary ostia. There was a decrease in thrombus burden when
scan was repeated at 1-year post TAVI, with no adverse or embolic
events.
4. Discussion
The main finding of this study is that TAVI is feasible in ACHD pa-
tients, even though it is technically complex and challenging. Even in the
very high-risk group described, where patients were not deemed good
surgical candidates, there appears to be a favourable safety profile.
Fig. 5. CT images pre and post-procedure in a patient with corrected TGA.
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In this patient population, the use of the Society of Thoracic Surgeons
score and EuroSCORE may not reflect the risk of AoV surgery in the
presence of complex congenital anatomy [7–9]. At our centre
decision-making was truly multi-disciplinary; the team involved in the
pre-procedure planning consisted of structural and congenital heart dis-
ease interventionalists, congenital cardiothoracic surgeons, cardiac im-
aging specialists with expertise in structural and congenital imaging, and
cardiac anaesthetists.4.2. Choice of valves
The majority of our patients were young and did not have the classic
degenerative calcific trileaflet AS that TAVI valves were designed for.
Significant AoV lesions in the ACHD population can be due to either
primary dysfunction as the result of an isolated AoV defect or part of a
more complex condition or secondary dysfunction due to aortic root
dilation, AoV leaflet prolapse or as a consequence of leaflet damage.
Significant AoV deterioration may occur following valve repair or
replacement with bioprostheses, homografts or autografts. Six patients
had native BAV, 5 ViV-TAVI in failed bioprostheses (2 ViV were in ho-
mografts) and 2 severe AR.
A theoretical concern for TAVI is durability in younger patients. A
recent study of 1403 patients reported long-term durability of TAVI [10].
49 patients showed bioprosthetic valve failure with a 7-year cumulative
incidence of moderate and severe structural valve deterioration of 7.0%
(95% CI, 5.6%–8.4%) and 4.2% (95% CI, 2.9%–5.5%), respectively.
However, the long-term assessment of durability is limited by the poor
survival of the population beyond 5 years. More studies are needed in a7
younger and lower-risk patient population who have had undergone
TAVI to determine long-term durability. Surgical and transcatheter bio-
prostheses share similar pericardial leaflet material and are both prone to
Ref. [1] structural valve deterioration in the form of calcification, leaflet
fibrosis, tear or flail [2], nonstructural valve deterioration in the form of
PAR, size mismatch [3], thrombosis and [4] endocarditis [11]. To avoid
the use of bioprosthetic valves, congenital surgeons tend to use Ross,
valve sparing repair and more recently the Ozaki procedure for ACHD
patients, but in the patients we describe, these options were not
considered possible.4.3. Procedural results
Passing the delivery systems through stented or surgically repaired
coarctation did not cause significant problems, requiring only minor wire
manipulation.
Valve positioning was problematic in two patients. Patient 3 with
corrected TGA had a systemic right ventricle, with a muscular systemic
right ventricular outflow tract and a large annulus requiring a 31mm
CoreValve. As this was not a recapturable and redeployable valve, we
initially accepted a low position. Pulling the valve up with a snare was
later successful. Patient 6 with a Fontan, single ventricle circulation and
pure AR with a thin and mobile resuspended valve in a 31mm tube graft
presented a particular problem. The 34mm Evolut R valve was being
used outside of its design envelope, and moved down into the ventricle
on release, probably because of the non-expandable nature of the pros-
thetic tube in which the valve had been resuspended – known as “melon-
seeding”, and exacerbated by the absence of calcification. Whilst this was
predictable (complication), the patient was young and deemed inoper-
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bypass (subsequently improved with balloon occlusion) is likely to have
contributed to the brain hypoperfusion injury. TAVI in native severe AR
has been associated with increased embolization, migration and signifi-
cant PAR due to the absence of annular and leaflet calcification, dilata-
tion of the ascending aorta and increased stroke volume.
In homografts and stented surgical tissue valves, TAVI expansion can
be limited. Some stented surgical valves can be post dilated with a Kevlar
balloon to high pressure safely rupturing the surgical stent [12]. Heavily
calcified degenerative homograft valve replacements do not always allow
full expansion of the TAVI valve. ViV-TAVI is associated with coronary
obstruction [13, 14] so careful pre-procedural planning is essential to
identify high-risk features, such as low coronary heights, short virtual
TAVI to coronary ostial distance, shallow sinuses of Valsalva and low
sinotubular junction [15].
Patients with BAV morphology have increased risk of malpositioning,
elliptical shape of the aortic annulus, eccentric valve calcifications and
dilated ascending aorta [16–18]. Patient 2 had a highly eccentric BAV, as
well as a calcified coarctation, (where the balloon expandable valve was
a little high on one leaflet and a little low on the other), but crossing the
coarctation was uncomplicated and there was mild PAR at 3 year follow
up. (Our practice is to usually use self-expanding Medtronic valves for
BAV as it provides a longer sealing zone, although this patient had a
horizontal aorta, which led us to choose an Edwards valve.) New gen-
eration devices are being developed to improve outcomes by the devel-
opment of external sealing cuffs, better deliverability, retrievability and
repositioning capabilities or unique anchoring mechanisms [19–21].
4.4. Expansion of the TAVI population
To the best of our knowledge, this is the first study reporting the
feasibility and effectiveness of TAVI in an ACHD population. Only three
case reports have been published: 1)Turner's syndrome with severe
symptomatic unicuspid AS, surgical correction of CoA with multiple
comorbidities, 2) multiple surgical procedures for atrioventricular septal
defect with severe AR and severe left ventricular function as a bridge to
heart transplant and 3)surgically repaired double outlet right ventricle
with severe AS and liver cirrhosis due hepatitis C in need of liver trans-
plant [22–24].
The use of TAVI continues to grow for BAV, ViV treatment of
degenerated bioprostheses and native AR. As the lifespan of ACHD pa-
tients increase, the need for procedures later in life will also increase,
fuelling the rise of transcatheter interventions. This series includes young
patients where valve longevity is important, as well as older patients with
specific technical considerations, such as traversing coarctation repairs
or stents, and complex aortic root anatomy, such as an anterior aorta
attached to a muscular outflow tract, homografts and single ventricle
physiology. TAVI is an appealing alternative to conventional open-heart
surgery for those with severe AoV lesions, reducing sternotomies and
blood transfusion. (Avoiding transfusion is particularly important as
some young patients may be future candidates for heart transplantation.)
A recent study with encouraging results showed ViV-TAVI had better
short-term outcomes than redo SAVR (0.44–0.88; p¼ 0.03) and no sig-
nificant difference of combined endpoints on long-term follow-up
(18.6%/year vs. 21.9%/year; p¼ 0.34) [25].
However, careful evaluation and assessment of clinical factors and
complex anatomy must be considered during the decision-making pro-
cess in centres with expertise in both ACHD and TAVI. In the latest ACHD
guidelines, TAVI treatment is a therapeutic option in “very rare cases
with high surgical risk, when technically feasible” [26].
4.5. Study limitations
The aim of this study was to report initial outcomes of patients un-
dergoing TAVI for complex congenital heart disease at a single institution
and appears to be the first report of a series of TAVI procedures in this
patient group. The major limitation is the relatively small number of
S. Moharem-Elgamal et al. International Journal of Cardiology Congenital Heart Disease 3 (2021) 100116patients, and its retrospective nature.
5. Conclusions
TAVI appears to be feasible and effective in a group of ACHD patients
with heterogeneous anatomical situations and age, deemed very high risk
for conventional surgery by the MDT. Due to the variable nature of ACHD
patients, large randomized trials are unlikely to be performed. Never-
theless, these patients have frequently had multiple cardiac operations at
a young age and have much to gain by deferring or avoiding further
sternotomies. Furthermore, many have a small annulus where a simple
stented surgical AoV replacement decreases the effective orifice area.
ACHD patients should be considered as potential candidates for TAVI if
AoV intervention is needed.
5.1. Impact on daily practice
TAVI for ACHD patients requires multidisciplinary team discussion,
meticulous imaging and adequate back up during the procedure. TAVI
appears to be a viable alternative treatment option when surgery is not a
good option. A larger number of patients and long-term follow-up studies
are needed to confirm the safety and durability of this method and guide
patient selection.
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